


IN THE CLAIMS

Please replace claims 1, 3, 4 and 5 with new claims 1, 3, 4 and 5 as follows, and please cancel claim 9 without prejudice or disclaimer of the subject matter thereof.

IN THE CLAIMS (Clean Sheet)

1. (Twice Amended) A serine protease inhibitor having the formula (I),



in which

J is H, R¹, R¹-O-C(O)-, R¹-C(O)-, R¹-SO₂-, R³OOC-(CHR²)_p-,
(R^{2a}, R^{2b})N-CO-(CHR²)_p- or Het-CO-(CHR²)_p-;

W is an amino-acid of the formula -NH-CHR¹-C(O)-,

-NR⁴-CH((CH₂)_qC(O)OR¹)-C(O)-,


-NR⁴-CH((CH₂)_qC(O)N(R^{2a}, R^{2b}))-C(O)-,

-NR⁴-CH((CH₂)_qC(O)Het)-C(O)-,

D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq, D-3

Piq, glutamyl or a (C₁-C₆) alkylester thereof;

E is -NR²-CH₂- or the fragment



, which is unsubstituted or substituted

with (1-6C)alkyl, (1-6C)alkoxy or benzyloxy;

R¹ is selected from (1-12C)alkyl,

(2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and (3-

12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted

or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy, oxo,

OH, CF₃ or halogen, and from

(6-14C)aryl, (7-15C)aralkyl, (8-16C)aralkenyl and

(14-20C)(bisary)alkyl, wherein the aryl groups are

unsubstituted or substituted with (1-6C)alkyl,

(3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF₃ or halogen;

R², R^{2a} and R^{2b} are each independently selected from

H, (1-8C)alkyl, (3-8C)alkenyl, (3-8C)alkynyl,


(3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which

are unsubstituted or substituted with
 (3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen, and from
 (6-14C)aryl and (7-15C)aralkyl, wherein the aryl groups are
 unsubstituted or substituted with
 (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen;
 R^3 is the same as R^2 or is Het-(1-6C)alkyl;
 R^4 is H or (1-3C)alkyl;
 X and Y are CH or N, with the proviso that they are not
 both N;
 Het is a 4-, 5- or 6-membered heterocycle containing
 one or more heteroatoms selected from O, N and S;
 m is 1 or 2;
 p is 1, 2 or 3;
 q is 1, 2 or 3;
 t is 2, 3 or 4;
 or a pharmaceutically acceptable addition salt or
 solvate thereof.

3. (Twice Amended) The serine protease inhibitor according
 to claim 2, wherein

J is H, $R^1 R^1-SO_2-$, $R^3OOC-(CHR^2)_p-$,
 $(R^{2a}, R^{2b})N-CO-(CHR^2)_p-$ or $Het-CO(CHR^2)_p-$;

W is an amino-acid of the formula $-NH-CHR^1-C(O)-$,
 $-NR^4-CH((CH_2)_qC(O)OR^1)-C(O)-$,
 $-NR^4-CH((CH_2)_qC(O)N(R^{2a}, R^{2b}))-C(O)-$,
 E is $-N(3-6C)cycloalkyl-CH_2-$ or the fragment



, which is unsubstituted or
 substituted with (1-6C)alkyl or
 1-6C)alkoxy;

R^1 is selected from (1-12C)alkyl, (3-12C)cycloalkyl and

(3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy or oxo, and from (6-14C)aryl, (7-15C)aralkyl and (14-20C)(bisaryl)alkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF₃ or halogen;

R² is H;

B²
R^{2a} and R^{2b} are each independently selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy and from (6-14C)aryl and (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen;

R³ is selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy, and from (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen and from Het-(1-6C)alkyl;

p is 1;

q is 2;

t is 3 or 4.

4. (Twice Amended) The serine protease inhibitor according to claim 3, wherein

W is an amino-acid of the formula -NH-CHR¹-C(O)- or glutamyl or an (1-6C)alkylester thereof;

R¹ is selected from (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl

or (1-6C)alkoxy, and from (6-14C)aryl,
(7-15C)aralkyl and (14-20C)(bisary)alkyl, wherein the
aryl groups are unsubstituted or substituted with
(1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy or
halogen; and


β^2 R^3 is selected from (1-8C)alkyl and (3-8C)cycloalkyl,
which are unsubstituted or substituted with
(3-6C)cycloalkyl or (1-6C)alkoxy, and from
(7-15C)aralkyl, wherein the aryl groups are
unsubstituted or substituted with (1-6C)alkyl,
(3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen and
from Het-(1-6C)alkyl.

5. (Twice Amended) The serine protease inhibitor according
to claim 4, wherein

J is $-CH_2COO(1-6C)alkyl$, (3-8C)cycloalkyl,
 $-SO_2-10-camphor$, $-CH_2CONHphenyl$ or $-CH_2CONH(3-8C)cycloalkyl$;

W is D-cyclohexylalaninyl, D-phenylalaninyl,
D-diphenylalaninyl or glutamyl, or an (1-6C)alkylester thereof; and

E is the fragment



, wherein t is 3 or 4.